Sun says it didn't run up Ranbaxy shares before deal; FDA approves label update for Teva's Synribo;

@FiercePharma: Pfizer's 'weak' Q1 numbers bolster case for AZ buy--and post-merger split, too. More | Follow @FiercePharma

@TracyStaton: Forest founder, CEO set for $100M-plus yield from Actavis buyout. Article | Follow @TracyStaton

@EricPFierce: With all of the deals going on, Teva CEO thinks a buy in biosimilars might be a move it would make. Story | Follow @EricPFierce

@CarlyHFierce: ICYMI Friday: Positive H7N9 data could help Novartis hawk flu vax business. Article | Follow @CarlyHFierce

> India's Sun Pharma says its Silverstreet Developers unit had no role to play in the run-up of Ranbaxy shares before Sun's deal announcement for the troubled generics maker. Story

> Novartis' ($NVS) Signifor showed superior efficacy in acromegaly patients not controlled on first-generation somatostatin analogues. Release

> The FDA has approved a label change for Teva's ($TEVA) Synribo injection that allows for home administration. Release

> Former Forest Laboratories ($FRX) SVP and general counsel has joined Lowenstein Sandler's life sciences practice. Release

> A soldier claimed Pfizer's ($PFE) anti-smoking drug Chantix drove him to commit murder. More

> Biocon, which makes a scorpion anti-venom drug, has received an FDA warning letter for a plant in Mexico City. More

> Italy is leading an international effort to catch a criminal drug-theft ring. More

> Indian drugmaker Cipla says essential drugs should not be sold under "monopoly." More

> Sanofi ($SNY) says the World Health Organization (WHO) has approved its Shan5 vaccine for purchase from UN agencies. Release

Medical Device News

@FierceMedDev: BioFire Diagnostics wins FDA clearance for innovative GI panel. Article | Follow @FierceMedDev

@VarunSaxena2: Apple on medical tech hiring spree, a possible hint of iWatch plans. Story via Reuters | Follow @VarunSaxena2

@EmilyWFierce: New Dx machine from student at MIT uses magnets and lasers to quickly spot. More from the Boston Globe | Follow @EmilyWFierce

@MichaelGFierce: Oramed's oral insulin PhIIa details show a compromised study, and shares continue to fall. Story via FierceDrugDelivery | Follow @MichaelGFierce

> Hospira recalls infusion pump docking station. Piece

> Alere shakes up boardroom, embarks on strategic review. More

> Volcano ticks up sales in Q2 as losses widen. News

Biotech News

@FierceBiotech: Bristol-Myers' armed antibody partner Ambrx shoots for an $86M IPO. Story | Follow @FierceBiotech

@JohnCFierce: Pfizer down more than 2% on some miserable Q1 numbers. Only more fuel for the M&A fire. | Follow @JohnCFierce

@DamianFierce: It's FDA decision day for epanova, the cardio drug AstraZeneca picked up in its $443M deal for Omthera. | Follow @DamianFierce

@EmilyMFierce: As MERS arrives in U.S., Novavax, UofMaryland report positive preclinical results for MERS vaccine. Story via FierceBiotech Research | Follow @EmilyMFierce

> Global R&D centers brace for another blow as Pfizer circles AstraZeneca. More

> Novartis' long-acting Signifor passes PhIII test for acromegaly. Story

> Regeneron jumps into next-gen gene therapy tech with $640M eye drug deal. Article

CRO News

> Covance slips after narrowing its 2014 ambitions. Article

> Charles River ticks up revenue M&A on tap. More

> Quintiles keeps rolling with another $1B quarter. Report

> Parexel boosts revenue with eyes on a $1.9B year. Article

> Icon cranks up its 2014 expectations after another leap. Story

Biotech IT News

> Bina, SAS and others pitch new tools to boost biopharma R&D. Article

> Novartis steps up MS digital presence with iPhone app. Item

> Buzz: Google Ventures leading $100M round in oncology Big Data platform. More

> Canada to set up cancer cloud computing facility. News

> Medidata unveils Sanofi deal as it looks to recover from rocky April. Story

And Finally... Do statins change our eating habits? More (sub. req.)

Suggested Articles

In an era of limited access to key decision makers, how are you mobilizing your field force to communicate the value of your brands and real-world evidence?

Novo Nordisk’s Ozempic is off to a blazing start, and the company just threw more fuel on the fire with a pair of trial wins.

Biosims to Roche's Big 3 cancer drugs will chisel out a $10 billion sales gap by 2023, but newer meds could chip in $16.3 billion, the drugmaker says.